177.88
Iqvia Holdings Inc stock is traded at $177.88, with a volume of 1.78M.
It is up +2.25% in the last 24 hours and down -12.18% over the past month.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
See More
Previous Close:
$173.96
Open:
$174.73
24h Volume:
1.78M
Relative Volume:
0.92
Market Cap:
$30.19B
Revenue:
$16.30B
Net Income/Loss:
$1.36B
P/E Ratio:
22.64
EPS:
7.8573
Net Cash Flow:
$2.05B
1W Performance:
+9.86%
1M Performance:
-12.18%
6M Performance:
-3.37%
1Y Performance:
-3.10%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
177.88 | 29.52B | 16.30B | 1.36B | 2.05B | 7.8573 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
Why IQVIA (IQV) Is Up 9.9% After Mixed Q4 Results and AI-Linked Outlook Reset - simplywall.st
Jim Cramer on IQVIA: "I Like the Business Very Much, I Just Don't Know Whether This Is the Right Stock to Play It" - Finviz
Jim Cramer on IQVIA: “I Like the Business Very Much, I Just Don’t Know Whether This Is the Right Stock to Play It” - Yahoo Finance
Is IQVIA (IQV) Offering An Opportunity After Recent Share Price Declines? - Yahoo Finance
IQVIA Holdings Inc (IQV)'s Winning Formula: Financial Metrics an - GuruFocus
IQVIA Holdings (IQV): RBC Capital Initiates Coverage with "Outpe - GuruFocus
11 Analysts Assess IQVIA Holdings: What You Need To Know - Benzinga
IQVIA Rose 7% This Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says - marketscreener.com
Strive Asset Management LLC Buys Shares of 91,856 IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA (NYSE:IQV) Now Covered by Royal Bank Of Canada - MarketBeat
Assessing IQVIA Holdings (IQV) Valuation After Analyst Revisions And AI Disruption Concerns - simplywall.st
IQVIA Holdings Inc. $IQV Shares Bought by Elo Mutual Pension Insurance Co - MarketBeat
RBC Capital initiates IQVIA Holdings stock at Outperform on trial activity outlook - Investing.com Australia
IQV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference - 01net
IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference - 01net
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Analysts at Mizuho Remain Bullish on IQVIA (IQV) Following Q4 Results - Yahoo Finance
IQVIA Holdings, Inc. (IQV) Stock Analysis: A 32% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
IQVIA Holdings Inc. $IQV Holdings Decreased by Laurel Wealth Advisors LLC - MarketBeat
Real World Evidence Solutions Market Is Going to Boom Rapidly | - openPR.com
IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IQVIA Acquires Charles River Assets for $145 Million: Here’s the Street’s Scenario for 70% Upside - TIKR.com
TD Asset Management Inc Grows Stock Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Handelsbanken Fonder AB Sells 52,327 Shares of IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA HOLDINGS INC. ($IQV) CEO 2025 Pay Revealed - Quiver Quantitative
IQVIA Holdings Hits Day High with Strong 5.39% Intraday Surge - Markets Mojo
Keystone Investors PTE Ltd. Has $27.78 Million Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Erste Asset Management GmbH Trims Stock Position in IQVIA Holdings Inc. $IQV - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 17,121 Shares of IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder (NYSE:IQV) - Seeking Alpha
IQVIA Releases its 2025 Sustainability Report - 01net
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
11 Most Undervalued AI Stocks to Buy Now - Insider Monkey
Primecap Management Co. CA Has $89.11 Million Stock Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Artisan Partners Limited Partnership Raises Position in IQVIA Holdings Inc. $IQV - MarketBeat
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly
Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings? - Finviz
IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity - Insider Monkey
IQVIA to acquire Charles River drug discovery assets - Yahoo Finance
3 Reasons to Sell IQV and 1 Stock to Buy Instead - Finviz
IQVIA Acquisition Expands Drug Discovery Role And Highlights Valuation Gap - Yahoo Finance
IQVIA to acquire drug discovery assets from Charles River Labs By Investing.com - Investing.com Australia
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Activist investor prompts sale of Charles River CDMO business, U.S. and European sites - The Business Journals
IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE - marketscreener.com
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities - 01net
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans - Benzinga
Did AI‑Driven Obesity Research Wins and Strong 2025 Results Just Shift IQVIA's (IQV) Investment Narrative? - simplywall.st
IQVIA to acquire drug discovery assets from Charles River Labs - Investing.com
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):